Substituted pteridines for the treatment of inflammatory diseases

1. A compound of the formula 1

wherein

R 1 denotes a pyrrolidin-1-yl, piperidin-1-yl or 4-piperidinyl;

R 2 denotes halogen, OR 2.1 , SR 2.1 , NR 2.1 R 2.2 or a group selected from among aryl, het and hetaryl, optionally substituted by a group selected from among C 1-6 -alkyl, O—C 1-6 -alkyl, C 3-6 -cycloalkyl, C 7-11 -aralkyl and N(C 1-4 -alkyl) 2 ;

R 2.1 denotes H, C 1-4 -alkyl, aryl or C 7-11 -aralkyl;

R 2.2 denotes H, C 1-4 -alkyl, aryl or C 7-11 -aralkyl;

R 3 denotes a group of formula 1a,

wherein

A denotes aryl or hetaryl;

X denotes NR 3.2 ;

Y denotes C 1-4 -alkylene, optionally substituted by one or more R 3.3

m denotes 0, 1, 2 or 3;

R 3.1 each independently of one another denote C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkyl-CONR 3.1.1 R 3.1.2 , —C 1-6 -alkyl-NR 3.1.1 R 3.1.2 , OR 3.1.1 , O—C 1-6 -haloalkyl, NHCOR 3.1.1 , SO 2 R 3.1.1 , aryl, halogen, CN, OH, CONR 3.1.1 R 3.1.2 ; or

R 3.1 together with two atoms of A forms a 5- or 6-membered carbocyclic ring or a 5- or 6-membered heterocyclic ring which optionally contains one or more oxygen or nitrogen atoms;

R 3.1.1 denotes H or C 1-6 -alkyl,

R 3.1.2 denotes H or C 1-6 -alkyl,

R 3.2 denotes H or C 1-6 -alkyl;

R 3.3 each independently of one another denote C 1-6 -alkyl, C 1-6 -alkyl-OH, C 3-6 -cycloalkyl-OH, COOR 3.3.1 , CONR 3.3.1 R 3.3.2 ; or

R 3.3 together with one or two carbon atoms of Y forms a carbocyclic ring with 3, 4, 5 or 6 carbon atoms

R 3.3.1 denotes H or C 1-6 -alkyl;

R 3.3.2 denotes H or C 1-6 -alkyl;

R 4 denotes a group selected from among C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, OR 4.1 , SR 4.1 , C 1-6 -haloalkyl, NR 4.1 R 4.2 or a group selected from among aryl, het and hetaryl, optionally substituted by one or more groups selected from among C 1-6 -alkyl, C 1-6 -haloalkyl, CN, O—C 1-6 -alkyl and halogen,

R 4.1 denotes H, C 1-6 -alkyl, aryl or C 7-11 -aralkyl;

R 4.2 denotes H, C 1-6 -alkyl, aryl or C 7-11 -aralkyl;

or a pharmacologically acceptable salt thereof,

wherein het or heterocyclic ring is either a five-, six- or seven-membered, saturated or unsaturated heterocyclic ring or a 5-10 membered, bicyclic heteroring which contains one, two or three heteroatoms selected from among oxygen, sulphur and nitrogen, while the ring may be linked to the molecule through a carbon or nitrogen atom and wherein hetaryl denotes five- or six-membered heterocyclic aromatic group or 5-10 membered bicyclic heteroaryl ring which contains one, two or three heteroatoms selected from among oxygen, sulphur and nitrogen and contains sufficient conjugated double bonds to form an aromatic system, while the ring may be linked to the molecule through a carbon or nitrogen atom.

2. A compound of the formula 1, according to claim 1 , wherein

R 3 denotes a group of formula 1a,

wherein

A denotes aryl or hetaryl;

X denotes NR 3.2 ;

Y denotes C 1-4 -alkylene, optionally substituted by one or more R 3.3

m denotes 0, 1 or 2;

R 3.1 each independently of one another denote C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkyl-CONH 2 , —C 1-6 -alkyl-NH 2 , O—C 1-6 -alkyl, O—C 1-6 -haloalkyl, NHCO—C 1-6 -alkyl, SO 2 —C 1-6 -alkyl, aryl, halogen, CN, OH, CONH 2; or

R 3.1 together with two atoms of A forms a 5- or 6-membered carbocyclic ring or a 5- or 6-membered heterocyclic ring which may contain one or more oxygen or nitrogen atoms;

R 3.2 denotes H or C 1-6 -alkyl;

R 3.3 each independently of one another denote C 1-6 -alkyl, C 1-6 -alkyl-OH, C 3-6 -cycloalkyl-OH, COO—C 1-6 -alkyl, COOH, CONH 2; or

R 3.3 together with one or two carbon atoms of Y forms a carbocyclic ring with 3, 5 or 6 carbon atoms

R 4 denotes a group selected from among C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -haloalkyl, NR 4.1 R 4.2 or a group selected from among aryl, het and hetaryl, optionally substituted by one or more groups selected from among C 1-6 -alkyl, C 1-6 -haloalkyl, CN, O—C 1-6 -alkyl, halogen,

R 4.1 denotes H or C 1-6 -alkyl;

R 4.2 denotes C 1-6 -alkyl or aryl;

or a pharmacologically acceptable salt thereof.

3. A compound of the formula 1 according to claim 1 , wherein

R 4 denotes C 3-6 -cycloalkyl;

or a pharmacologically acceptable salt thereof.

4. A compound of the formula 1 according to claim 1 , wherein

R 3 denotes a group of formula 1a,

wherein

A denotes aryl or hetaryl;

X denotes NH;

Y denotes C 1-4 -alkylene, optionally substituted by one or more R 3.3

m denotes 0, 1 or 2;

R 3.1 each independently of one another denote C 1-4 -alkyl, C 1-4 -haloalkyl, C 1-4 -alkyl-CONH 2 , C 1-4 -alkyl-NH 2 , O—C 1-4 -alkyl, O—C 1-4 -haloalkyl, NHCO—C 1-4 -alkyl, SO 2 —C 1-4 -alkyl, halogen, CN, OH, or CONH 2 ;

R 3.3 each independently of one another denote C 1-4 -alkyl, C 1-4 -alkyl-OH, C 3-4 -cycloalkyl-OH, COO—C 1-4 -alkyl, COOH, CONH 2; or

R 3.3 together with one or two carbon atoms of Y forms a carbocyclic ring with 3, 5 or 6 carbon atoms

or a pharmacologically acceptable salt thereof.

5. A compound of the formula 1 according to claim 1 , wherein

R 3 denotes a group of formula 1a,

wherein

A denotes aryl or hetaryl;

X denotes NH;

Y denotes C 1-4 -alkylene, optionally substituted by one or two R 3.3

m denotes 0, 1 or 2;

R 3.1 each independently of one another denote C 1-4 -alkyl, C 1-4 -haloalkyl, O—C 1-4 -alkyl, O—C 1-4 -haloalkyl, halogen, CN or OH;

R 3.3 each independently of one another denote C 1-4 -alkyl, COOH or CONH 2 ; or

R 3.3 together with one or two carbon atoms of Y forms a carbocyclic ring with 3 carbon atoms

or a pharmacologically acceptable salt thereof.

6. A compound of the formula 1 according to claim 1 , wherein

R 1 denotes a group selected from among

R 2 denotes a group selected from among chlorine,

R 3 denotes a group selected from among

R 4 denotes a group selected from among methyl, ethyl, propyl, 2-methylpropyl, methoxy, CF 3 , NMe 2 , NEt 2 ,

 or a pharmacologically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.